7
Clinical Trials associated with Bevacizumab biosimilar(Cipla Ltd.)Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: PRIME
This phase Ib trial determines if samples from a patient's cancer can be tested to find combinations of drugs that provide clinical benefit for the kind of cancer the patient has. This study is also being done to understand why cancer drugs can stop working and how different cancers in different people respond to different types of therapy.
A Phase II, Single-Arm Open-Label Study of the Combination of Atezolizumab and Bevacizumab in Rare Solid Tumors
This phase II trial studies how well atezolizumab and bevacizumab work in treating patients with rare solid tumors. Immunotherapy with monoclonal antibodies, such as atezolizumab and bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
A Randomized, Double-blind, Multicentric,Parallel-group Study Comparing Efficacy, Safety andImmunogenicity of CBT124, a Candidate BiosimilarBevacizumab in Combination with Carboplatin andPaclitaxel with EU-sourced Avastin® in Combinationwith Carboplatin and Paclitaxel in First-line Treatmentfor Subjects with Stage IV (Unresectable RecurrentDisease or Metastatic) Non-squamous Non-Small CellLung Cancer (NSCLC)
100 Clinical Results associated with Bevacizumab biosimilar(Cipla Ltd.)
100 Translational Medicine associated with Bevacizumab biosimilar(Cipla Ltd.)
100 Patents (Medical) associated with Bevacizumab biosimilar(Cipla Ltd.)
100 Deals associated with Bevacizumab biosimilar(Cipla Ltd.)